David Sidransky - Orgenesis Director
| ORGS Stock | USD 0.52 0.01 1.96% |
Director
Dr. David Sidransky, M.D., was appointed as Director of Orgenesis Inc., effective July 17, 2013. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky was the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicines Department of Otolaryngology and Professor of Oncology, Cellular Molecular Medicine, Urology, Genetics, and Pathology at the John Hopkins University School of Medicine. Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the world in the field of oncology during the past decade, with over 460 peerreviewed publications. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. Dr. Sidransky has served as Vice Chairman of the Board of Directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is serving, or has served on, the scientific advisory boards of MedImmune, Roche, Amgen and Veridex, LLC, among others, and is currently on the board of KV Pharmaceutical, Rosetta Genomics and Champions Oncology, Inc. Dr. Sidransky served as Director of the American Association for Cancer Research . He was the chairperson of AACR International Conferences on Molecular Diagnostics in Cancer Therapeutic Development Maximizing Opportunities for Personalized Treatment. since 2013.
| Age | 57 |
| Tenure | 11 years |
| Address | 20271 Goldenrod Lane, Germantown, MD, United States, 20876 |
| Phone | 480 659 6404 |
| Web | https://www.orgenesis.com |
David Sidransky Latest Insider Activity
Tracking and analyzing the buying and selling activities of David Sidransky against Orgenesis stock is an integral part of due diligence when investing in Orgenesis. David Sidransky insider activity provides valuable insight into whether Orgenesis is net buyers or sellers over its current business cycle. Note, Orgenesis insiders must abide by specific rules, including filing SEC forms every time they buy or sell Orgenesis'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
David Sidransky over three weeks ago Acquisition by David Sidransky of tradable shares of Orgenesis at 5.42 subject to Rule 16b-3 | ||
David Sidransky over three months ago Acquisition by David Sidransky of 15495 shares of Champions Oncology subject to Rule 16b-3 | ||
David Sidransky over six months ago Acquisition by David Sidransky of 11480 shares of Champions Oncology subject to Rule 16b-3 |
Orgenesis Management Efficiency
The company has return on total asset (ROA) of (0.6186) % which means that it has lost $0.6186 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.3908) %, meaning that it created substantial loss on money invested by shareholders. Orgenesis' management efficiency ratios could be used to measure how well Orgenesis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 30.36 in 2024, whereas Return On Tangible Assets are likely to drop (9.74) in 2024. At this time, Orgenesis' Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 1.8 M in 2024, whereas Total Current Assets are likely to drop slightly above 15.1 M in 2024.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Stephen Forman | Lixte Biotechnology Holdings | N/A | |
| Yun Yen | Lixte Biotechnology Holdings | N/A | |
| Gilbert Labrucherie | Rezolute | 44 | |
| George Schaefer | AN2 Therapeutics | 70 | |
| Kathleen Mullinix | Lixte Biotechnology Holdings | 69 | |
| David Welch | Rezolute | 56 | |
| Julie Hill | AN2 Therapeutics | 69 | |
| Antonio Neri | AN2 Therapeutics | 49 | |
| Ramiro Peru | AN2 Therapeutics | 60 | |
| William Ryan | AN2 Therapeutics | 71 | |
| John Short | AN2 Therapeutics | 70 | |
| Elizabeth Tallett | AN2 Therapeutics | 67 | |
| Will Feest | AN2 Therapeutics | N/A | |
| Tae Kim | Rezolute | 34 | |
| Young Sung | Rezolute | N/A | |
| Bahija Jallal | AN2 Therapeutics | N/A | |
| Kerry Clark | AN2 Therapeutics | 63 | |
| Robert Dixon | AN2 Therapeutics | 60 | |
| Winson Ho | Lixte Biotechnology Holdings | N/A | |
| Philip Palmedo | Lixte Biotechnology Holdings | 80 | |
| Samir Patel | Rezolute | 46 | |
Management Performance
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.62 |
Orgenesis Leadership Team
Elected by the shareholders, the Orgenesis' board of directors comprises two types of representatives: Orgenesis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Orgenesis. The board's role is to monitor Orgenesis' management team and ensure that shareholders' interests are well served. Orgenesis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Orgenesis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Sidransky, Director | ||
| Osher Rheinisch, General Officer | ||
| Yaron Adler, Director | ||
| Pierre Lammeretz, Interim Officer | ||
| Neil Reithinger, CFO, Treasurer and Secretary | ||
| Joseph Carpinelli, Chief Octomera | ||
| Etti Hanochi, Director | ||
| Hugues Bultot, Director | ||
| Chris Buyse, Director | ||
| Dan Slonim, COO Israel | ||
| Sarah Ferber, Chief Scientific Officer | ||
| Vincent Vandamme, VP Strategy | ||
| Victor Miller, Chief Officer | ||
| Neil CPA, S CFO | ||
| Shimon Hassin, Chief Officer | ||
| Marie Bouillez, Director | ||
| Efrat Kunik, Chief Officer | ||
| Scott Carmer, CEO of Orgenesis Maryland Inc | ||
| Evan Fishman, Chief Officer | ||
| Guy Yachin, Director | ||
| Vered MSc, CEO Board | ||
| Vered Caplan, Chairman of the Board, Interim President and CEO | ||
| Pr Ferber, Founder Officer |
Orgenesis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Orgenesis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.62 | ||||
| Operating Margin | (32.13) % | ||||
| Current Valuation | 38.84 M | ||||
| Shares Outstanding | 34.34 M | ||||
| Shares Owned By Insiders | 20.35 % | ||||
| Shares Owned By Institutions | 6.56 % | ||||
| Number Of Shares Shorted | 299.69 K | ||||
| Price To Earning | 7.52 X | ||||
| Price To Book | 1.39 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Orgenesis in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Orgenesis' short interest history, or implied volatility extrapolated from Orgenesis options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Orgenesis. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Orgenesis Stock please use our How to Invest in Orgenesis guide.Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Orgenesis Stock analysis
When running Orgenesis' price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Orgenesis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Orgenesis. If investors know Orgenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Orgenesis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.018 | Quarterly Revenue Growth (0.99) | Return On Assets (0.62) | Return On Equity (3.39) |
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Orgenesis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.